Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 17/20 | 0.59 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.50 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.50 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.50 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.50 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.50 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574863 | 0.93 | FAAH (0.67) | FAAH | |
| SCHEMBL1575929 | 0.92 | FAAH (0.60) | FAAHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1574927 | 0.90 | FAAH (0.61) | FAAHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1575492 | 0.90 | FAAH (0.59) | FAAHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1575902 | 0.89 | FAAH (0.50) | FAAHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1575324 | 0.89 | PRKAB2 (0.60) | FAAHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1575591 | 0.89 | FAAH (0.61) | FAAHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1575280 | 0.87 | FAAH (0.54) | FAAHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1575462 | 0.87 | FAAH (0.53) | FAAHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1574860 | 0.87 | PRKAB2 (0.57) | FAAHPRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308562-A2 | Azetidine ring compounds and drugs comprising the same | Ono Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | FAAH 3484/4885PRKAB2 3568/4885PRKAG1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.